<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00041288</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000069462</org_study_id>
    <secondary_id>UTSMC-0501228</secondary_id>
    <secondary_id>AMGEN-UTSMC-0501228</secondary_id>
    <secondary_id>IBMTR-SC-00-02.1</secondary_id>
    <secondary_id>ROCHE-UTSMC-0501228</secondary_id>
    <secondary_id>SPRI-UTSMC-0501228</secondary_id>
    <secondary_id>NCI-V02-1706</secondary_id>
    <nct_id>NCT00041288</nct_id>
  </id_info>
  <brief_title>Study Of Two Non-Myeloablative Stem Cell Transplant Strategies For Low-Grade Lymphoma And CLL</brief_title>
  <official_title>A Phase II Multicenter Randomized Study Of Two Non-Myeloablative Stem Cell Transplant Strategies For Low-Grade Lymphoma And Chronic Lymphocytic Leukemia (CLL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Texas Southwestern Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.&#xD;
      Peripheral stem cell transplantation may be able to replace immune cells that were destroyed&#xD;
      by chemotherapy or radiation therapy. Sometimes the transplanted cells are rejected by the&#xD;
      body's normal tissues. Cyclosporine, mycophenolate mofetil, methotrexate, and tacrolimus may&#xD;
      prevent this from happening.&#xD;
&#xD;
      PURPOSE: Randomized phase II trial to compare the effectiveness of fludarabine plus&#xD;
      total-body irradiation with that of combination chemotherapy followed by donor peripheral&#xD;
      stem cell transplantation in treating patients who have relapsed non-Hodgkin's lymphoma or&#xD;
      chronic lymphocytic leukemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Compare the 1-year overall survival rate of patients with relapsed low-grade&#xD;
           non-Hodgkin's lymphoma or chronic lymphocytic leukemia treated with fludarabine and&#xD;
           total body irradiation vs cyclophosphamide and fludarabine followed by allogeneic&#xD;
           peripheral blood stem cell transplantation and donor lymphocyte infusions.&#xD;
&#xD;
        -  Compare the toxic effects of these regimens in these patients.&#xD;
&#xD;
        -  Compare the incidence and severity of acute and chronic graft-versus-host disease in&#xD;
           patients treated with these regimens.&#xD;
&#xD;
        -  Compare the 1-year treatment-related mortality and infectious complications in patients&#xD;
           treated with these regimens.&#xD;
&#xD;
        -  Compare the efficacy of these treatment regimens, in terms of 1-year disease-free&#xD;
           survival, of these patients.&#xD;
&#xD;
        -  Compare the quality of life of patients treated with these regimens.&#xD;
&#xD;
      OUTLINE: This is a randomized, multicenter study. Patients are stratified according to&#xD;
      disease, age (less than 55 vs over 55), and participating transplantation center. Patients&#xD;
      are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
        -  Arm I: Patients receive fludarabine IV on days -4 to -2. Patients undergo total body&#xD;
           irradiation followed by allogeneic peripheral blood stem cell transplantation (PBSCT) on&#xD;
           day 0. Patients receive graft-versus-host disease (GVHD) prophylaxis comprising oral&#xD;
           cyclosporine twice daily on days -2 to 90 followed by a taper on days 90-150 and oral&#xD;
           mycophenolate mofetil twice daily on days 0-28.&#xD;
&#xD;
        -  Arm II: Patients receive fludarabine IV on days -6 to -2 and cyclophosphamide IV on days&#xD;
           -3 to -2. Patients undergo PBSCT on day 0. Patients receive GVHD prophylaxis comprising&#xD;
           methotrexate IV on days 1, 3, 6, and 11 and tacrolimus IV continuously and then orally&#xD;
           on days -2 to 90 followed by a taper on days 90-150.&#xD;
&#xD;
      At approximately day 180, patients with persistent disease, evidence of T-cell chimerism, and&#xD;
      no GVHD may receive up to 3 donor lymphocyte infusions administered every 1-2 months.&#xD;
&#xD;
      Quality of life is assessed at baseline, 1 month, every 3 months for 1 year, and then every 6&#xD;
      months for 1 year.&#xD;
&#xD;
      Patients are followed at 1 month, every 3 months for 1 year, and then annually for 2 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 100 patients (50 per treatment arm) will be accrued for this&#xD;
      study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Poor accrual and difficulty with multicenter logistics&#xD;
  </why_stopped>
  <start_date>October 2001</start_date>
  <completion_date type="Actual">January 2003</completion_date>
  <primary_completion_date type="Actual">January 2003</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Actual">10</enrollment>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>therapeutic allogeneic lymphocytes</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclosporine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fludarabine phosphate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mycophenolate mofetil</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tacrolimus</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of chronic lymphocytic leukemia or&#xD;
&#xD;
          -  Diagnosis of non-Hodgkin's lymphoma&#xD;
&#xD;
          -  Lymphoplasmacytic lymphoma&#xD;
&#xD;
          -  Grade I follicular small cleaved cell lymphoma&#xD;
&#xD;
          -  Grade II follicular mixed cell lymphoma&#xD;
&#xD;
          -  Diffuse small cleaved cell lymphoma&#xD;
&#xD;
          -  Small lymphocytic lymphoma&#xD;
&#xD;
          -  Relapsed after at least 1 course of prior therapy&#xD;
&#xD;
          -  Availability of a 6/6 human leukocyte antigen (HLA) A, B, and DR identical sibling&#xD;
             donor&#xD;
&#xD;
          -  Nonmyeloablative transplantation candidate&#xD;
&#xD;
          -  No clinically significant effusions or ascites that would preclude administration of&#xD;
             methotrexate&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        -Age: 18 to 75&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) 0-2 OR Zubrod 0-2&#xD;
&#xD;
          -  Life expectancy: At least 6 months&#xD;
&#xD;
          -  Hematopoietic: Not specified&#xD;
&#xD;
          -  Hepatic: Bilirubin no greater than 3 mg/dL&#xD;
&#xD;
          -  Renal: Creatinine no greater than 2 mg/dL&#xD;
&#xD;
          -  Cardiovascular: left ventricular ejection fraction (LVEF) at least 40% on multigated&#xD;
             acquisition (MUGA) scan or echocardiogram&#xD;
&#xD;
          -  Pulmonary: diffusing capacity of lung for carbon monoxide (DLCO) at least 50% of&#xD;
             predicted&#xD;
&#xD;
        OTHER:&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No uncontrolled bacterial, viral, fungal, or parasitic infection&#xD;
&#xD;
          -  Human Immunodeficiency Virus (HIV)1 and Human Immunodeficiency Virus (HIV)2 negative&#xD;
&#xD;
          -  No other active malignancy except basal cell skin cancer&#xD;
&#xD;
          -  No recent history of drug or alcohol abuse&#xD;
&#xD;
          -  No other primary disease or comorbid illness that would severely limit life expectancy&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY&#xD;
&#xD;
          -  Biologic therapy:See Disease Characteristics&#xD;
&#xD;
          -  Biologic therapy:Prior autologous bone marrow transplantation allowed if disease has&#xD;
             progressed after transplantation&#xD;
&#xD;
          -  Biologic therapy:No entry on study as part of a tandem autologous transplantation&#xD;
             followed by nonmyeloablative allograft protocol&#xD;
&#xD;
          -  Chemotherapy: Not specified&#xD;
&#xD;
          -  Endocrine therapy: Not specified&#xD;
&#xD;
          -  Radiotherapy:Not specified&#xD;
&#xD;
          -  Surgery: Not specified&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert H. Collins, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Simmons Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Centers</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Delaware Clinical &amp; Laboratory Physicians</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <zip>19713</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Hospital Cancer Institute</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center and Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612-9497</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Blood and Marrow Transplant Group of Georgia</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342-1601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Holden Comprehensive Cancer Center</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242-1009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Missouri Kansas City School of Medicine</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Hospital and Medical Center</name>
      <address>
        <city>Paterson</city>
        <state>New Jersey</state>
        <zip>07503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>James P. Wilmot Cancer Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Cancer Institute</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104-4283</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kimmel Cancer Center of Thomas Jefferson University - Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107-5541</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt-Ingram Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Simmons Cancer Center - Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235-8590</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Transplant Institute</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massey Cancer Center</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298-0037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin Comprehensive Cancer Center</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ottawa Regional Cancer Centre</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 1C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4S 1KN</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Toronto</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5S 1A8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital du Saint-Sacrament, Quebec</name>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <zip>G1S 4L8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>July 8, 2002</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>April 8, 2020</last_update_submitted>
  <last_update_submitted_qc>April 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Waldenstrom macroglobulinemia</keyword>
  <keyword>refractory chronic lymphocytic leukemia</keyword>
  <keyword>recurrent grade 1 follicular lymphoma</keyword>
  <keyword>recurrent grade 2 follicular lymphoma</keyword>
  <keyword>recurrent adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>recurrent small lymphocytic lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

